HIF1A and chronic myelogenous leukemia, BCR-ABL1 positive: Thus, the decreased sensitivity of CML cells to Crizotinib under hypoxic conditions is primarily mediated by the stabilization and increased activity of HIF1α, and inhibiting the function of HIF1α may restore the sensitivity of Crizotinib in hypoxic CML cells.